Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (NCT06136624)
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to OS in androgen receptor ligand binding domain (AR LBD) mutation-negative and -positive participants.
Who can join: Review the eligibility criteria below.
Location: University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) — Orange, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (288 Sites)
Showing the first 25 of 288 sites.
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) — Orange, California
- Stanford Cancer Center ( Site 0036) — Palo Alto, California
- Kaiser Permanente Riverside Medical Center ( Site 0099) — Riverside, California
- Anschutz Cancer Pavilion ( Site 0046) — Aurora, Colorado
- University of Colorado Health - Highlands Ranch Hospital ( Site 0111) — Highlands Ranch, Colorado
- Colorado Clinical Research ( Site 0067) — Lakewood, Colorado
- University of Colorado Health - Lone Tree Medical Center ( Site 0112) — Lone Tree, Colorado
- Yale-New Haven Hospital-Yale Cancer Center ( Site 0064) — New Haven, Connecticut
- Florida Cancer Specialists - South ( Site 7003) — Fort Myers, Florida
- Bruce W. Carter Veterans Affairs Medical Center ( Site 0082) — Miami, Florida
- University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0051) — Miami, Florida
- University of Illinois at Chicago ( Site 0105) — Chicago, Illinois
- University of Chicago Medical Center ( Site 0045) — Chicago, Illinois
- University of Iowa ( Site 0047) — Iowa City, Iowa
- University of Kentucky Chandler Medical Center ( Site 0048) — Lexington, Kentucky
- Ochsner Clinic Foundation ( Site 0108) — New Orleans, Louisiana
- Baltimore Veterans Affairs Medical Center ( Site 0069) — Baltimore, Maryland
- Greenebaum Comprehensive Cancer Center ( Site 0049) — Baltimore, Maryland
- Henry Ford Hospital ( Site 0015) — Detroit, Michigan
- Avera Cancer Institute - Marshall ( Site 0122) — Marshall, Minnesota
- M Health Fairview Clinics and Surgery Center ( Site 0019) — Minneapolis, Minnesota
- Metro-Minnesota Community Clinical Oncology ( Site 0014) — Saint Louis Park, Minnesota
- Hattiesburg Clinic Hematology/Oncology ( Site 0120) — Hattiesburg, Mississippi
- Washington University School of Medicine-Internal Medicine/Oncology ( Site 0062) — St Louis, Missouri
- University Of Nebraska Medical Center-Oncology/Hematology ( Site 0095) — Omaha, Nebraska
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer Metastatic
- REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer — New York, New York
- Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer — Duarte, California
- Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer — Victoria, British Columbia
- Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer — Baltimore, Maryland
- A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer — Duarte, California
Explore by condition: All Prostate Cancer Metastatic clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.